Navigation Links
New England Journal of Medicine Publishes New Data on Gardasil,,Merck's Cervical Cancer Vaccine

GARDASIL was assessed in 8915 women (GARDASIL N = 4666; placebo N = 4249) 18 to 26 years of age and female adolescents 9 to 17 years of age (GARDASIL N = 1471; placebo N = 583). Type-specific competitive immunoassays with type-specific standards were used to assess immunogenicity to each vaccine HPV type. These assays measured antibodies against neutralizing epitopes for each HPV type. The scales for these assays are unique to each HPV type; thus, comparisons across types and to other assays are not appropriate. Immune Response to GARDASIL The primary immunogenicity analyses were conducted in a per-protocol immunogenicity (PPI) population. This population consisted of individuals who were seronegative and PCR negative to the relevant HPV type(s) at enrollment, remained HPV PCR negative to the relevant HPV type(s) through 1 month Postdose 3 (Month 7), received all 3 vaccinations, and did not deviate from the study protocol in ways that could interfere with the effects of the vaccine. Overall, 99.8%, 99.8%, 99.8%, and 99.5% of girls and women who received GARDASIL became anti-HPV 6, anti-HPV 11, anti-HPV 16, and anti-HPV 18 seropositive, respectively, by 1 month Postdose 3 across all age groups tested. Anti-HPV 6, anti-HPV 11, anti-HPV 16, and anti-HPV 18 GMTs peaked at Month 7. GMTs declined through Month 24 and then stabilized through Month 36 at levels above baseline (Table 3). The duration of immunity following a complete schedule of immunization with GARDASIL has not been established. Table 3 Summary of Anti-HPV cLIA Geometric Mean Titers in the PPI* Population ---------------------------------------------------------------------- GARDASIL Aluminum-Containing Placebo N** = 276 N = 275 Study Time --------------------------------------------------------- Geometric Mean Titer Geomet
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine
2. Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis
3. Statement by Philip Home Chairman of the RECORD Study Steering Committee and Professor of Diabetes Medicine at Newcastle University in England
4. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
5. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
6. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
7. New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants
8. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
9. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
10. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
Post Your Comments:
(Date:2/26/2015)... 2015 RnRMarketResearch.com adds Corneal ... report to its store. This report p provides ... The report "Corneal Ulcers - Pipeline Review, H2 ... for Corneal Ulcers. Corneal Ulcers are primarily result ... viral infections & fungal infections. The symptoms of ...
(Date:2/26/2015)... , Feb. 26, 2015  Today the ... The psychological and physical side effects of pain ... opioid painkillers, such as Vicodin and Oxycontin, are safer ... Americans overdose on prescription painkillers than on heroin and ... and CEO of NSC. "Yet, these medications are marketed ...
(Date:2/26/2015)... WASHINGTON , Feb. 26, 2015  Mail-service ... consumers, employers and government health plans ... research released by the Pharmaceutical Care Management Association ... specialty drugs offers one of the easiest ways ... CEO Mark Merritt . "Policymakers should resist ...
Breaking Medicine Technology:Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 2Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 4Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 5National Safety Council: Opioid prescription painkillers have hidden, deadly side effects 2PCMA: Report Shows High-Tech Specialty and Mail-Service Pharmacies Will Reduce Costs for Texas Employers, Consumers and Public Programs by $23.3 Billion 2
... Cumberland Pharmaceuticals Inc.(Nasdaq: CPIX ) today announced the ... of the supplemental new drug application (sNDA) for the use ... acute liver failure. The review has been extended by three ... (PDUFA) goal date in December 2010. "We ...
... 20 The European Patent Office ("EPO") Board ... to uphold European Patent No. EP 1307131 for ... http://photos.prnewswire.com/prnh/20061011/SFW044LOGO ) (Logo: http://www.newscom.com/cgi-bin/prnh/20061011/SFW044LOGO ... 26th, keeps the GlideScope patent in force in ...
Cached Medicine Technology:Cumberland Pharmaceuticals Announces Extension of FDA Review of Acetadote® Supplemental New Drug Application 2Cumberland Pharmaceuticals Announces Extension of FDA Review of Acetadote® Supplemental New Drug Application 3European Patent Office Upholds GlideScope® Video Laryngoscope Patent 2
(Date:3/1/2015)... Barrel Mill ” was featured on NewsWatch as part of ... latest and coolest technology products and services available to consumers. ... conducted the review and shared with viewers how this oak ... Distillation of Alcohol, it's understood that oak is essential for ... that’ll help anyone achieve a barrel aged alcohol without having ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 In recent years ... number of practicing physicians as a way for them to ... education regarding Cannabis as medicine. Since the FDA still lists ... few resources available to licensed physicians that can help ... patient. Dr. Deborah Malka in Santa Cruz, CA is ...
(Date:2/28/2015)... With their commitment to achieving physical results ... exercise to their already robust library of oblique exercises. ... known as, is often performed on a stationary piece ... a relatively safe manner and can be performed by ... description of “Rope Pulls” is located in the oblique ...
(Date:2/28/2015)... Mew and Company, a Vancouver corporate ... provide business consulting services in addition to a variety ... and succession planning. Company finances are a complicated matter ... top of this, complex Canadian tax laws can make ... a result, Mew and Company works to advise their ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 For those ... in person, the Mesothelioma Applied Research Foundation ... on Tuesday, March 3, starting at 9:30 AM. , ... no registration. The broadcast can be accessed through any ... http://www.curemeso.org/symposium . , The Symposium is a unique event ...
Breaking Medicine News(10 mins):Health News:An Oak Infusion Spiral was Featured on NewsWatch Television on January 30, 2015 2Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2Health News:Mesothelioma Cancer Research Foundation Broadcasting Symposium Live 2
... VPHM ) today announced that the Committee ... Agency (EMEA) has granted orphan,drug designation for CAMVIA ... with impaired cell-mediated immunity. The EMEA,s,"Orphan Medicinal Product ... which may provide significant benefit to patients,suffering from ...
... American Cancer Society,is looking for individuals with or without ... the battle against cancer to serve on peer,review committees ... the,organization,s research and training grants. These "stakeholders" have,often had ... had a,family member with cancer, having been a cancer ...
... spirometry to clinical exams benefits those with symptoms , MONDAY, ... diagnosing and treating the lung illness known as stable ... American College of Physicians (ACP). , COPD, typically caused ... affects more than 5 percent of American adults and is ...
... Stock Exchange Symbol: AKL, MONTREAL, Nov. 12 ... development company focused on developing therapies for the,inhalation ... from,its pilot GHRH Phase II study. Within only ... significant stimulation of endogenous growth hormone (GH),secretion and ...
... Now has,selected its $7,500 Grand Prize winner in its ... walks away with the big prize,after a 3-month competition ... will receive $250 in the contest. The winning video ... "Brendan Hayward captured, in just 30 seconds, what ...
... Inc. (OTC Bulletin Board: INIS) announces financial results ... 30, 2007. REVENUE: Revenue for the three ... and $3,592,049 respectively, as compared to,$1,458,260 and $3,641,098 ... an increase of 2% for the three-month period ...
Cached Medicine News:Health News:ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM) 2Health News:ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM) 3Health News:ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM) 4Health News:American Cancer Society Seeks Volunteers to Help Decide Who Gets Research Grants 2Health News:New Guideline Targets Treatment of Stable COPD 2Health News:Akela Pharma announces final positive results from its growth hormone releasing hormone (GHRH) Phase II trial 2Health News:Akela Pharma announces final positive results from its growth hormone releasing hormone (GHRH) Phase II trial 3Health News:Akela Pharma announces final positive results from its growth hormone releasing hormone (GHRH) Phase II trial 4Health News:Akela Pharma announces final positive results from its growth hormone releasing hormone (GHRH) Phase II trial 5Health News:Psoriasis Cure Now Video Contest $7,500 Grand Prize Winner Announced 2Health News:International Isotopes Inc. Announces Third Quarter and Nine Months 2007 Financial Results 2Health News:International Isotopes Inc. Announces Third Quarter and Nine Months 2007 Financial Results 3Health News:International Isotopes Inc. Announces Third Quarter and Nine Months 2007 Financial Results 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: